Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Carcinoma, Hepatocellular 9Neoplasms 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Rituximab 161Cyclophosphamide 142fludarabine phosphate 89Peripheral Blood Stem Cell Transplantation 81Filgrastim 59Mycophenolic Acid 58Whole-Body Irradiation 53Cyclosporine 53Radiotherapy 52Lenalidomide 47Busulfan 45Tacrolimus 44Etoposide 43Antilymphocyte Serum 41Melphalan 37Methotrexate 31fludarabine 30Bortezomib 30Prednisone 28Bendamustine Hydrochloride 28Cytarabine 24Cord Blood Stem Cell Transplantation 23obinutuzumab 22Vincristine 22Methylprednisolone 21Flow Cytometry 21ibrutinib 19venetoclax 18sargramostim 17Granulocyte Colony-Stimulating Factor 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Pharmaceutical Preparations × Clear all
NCT00210353 2019-06-06

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 3 Completed
454 enrolled 16 charts
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT00210392 2015-03-30

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Terminated
12 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT00210327 2009-07-22

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Completed
33 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡